Phase 1/2 study of cetuximab plus capecitabine in elderly patients with kras-wild type mCRC who have no prior chemotherapy
Phase 1
Recruiting
- Conditions
- unresectable metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000004579
- Lead Sponsor
- Department of medical oncology, Cancer institute hospital, in Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 41
Inclusion Criteria
Not provided
Exclusion Criteria
Surgery or irradiation within 4weeks befor trial entry Uncontrolled comobirity Active infection unable to intake Pulmonary fibrosis, interstital pneumonia with previous medical history
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety/efficacy
- Secondary Outcome Measures
Name Time Method PFS,OS